Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.